TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23413202

Group type: EXPERIMENTAL
Intervention: Sparrow sirolimus‐eluting stent (Sparrow‐SES)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sparrow bare‐metal stent (Sparrow‐BMS)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional balloon‐expandable bare‐metal stent (BMS)
Number of subjects: 74
Study: 23518863

Group type: EXPERIMENTAL
Intervention: 52.5 mL of lidocaine 1%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 35 mL of lidocaine 1.5%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 26.25 mL of lidocaine 2%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups (1%, 1.5%, 2%)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1.5% group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2% group
Number of subjects: 90
Study: 21502675

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal band ligation (EVBL)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 73
Study: 18316985

Group type: EXPERIMENTAL
Intervention: Combined DTaP-IPV vaccine
Number of subjects: 4209

Group type: COMPARATOR
Intervention: Separate DTaP + IPV vaccines
Number of subjects: 4209
Study: 17137891

Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride as first‐line therapy in addition to conventional therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 26
Study: 14652415

Group type: EXPERIMENTAL
Intervention: Becaplermin
Number of subjects: 251

Group type: COMPARATOR
Intervention: Best clinical care alone
Number of subjects: 251
Study: 11113426

Group type: EXPERIMENTAL
Intervention: Beta blockade (atenolol and propranolol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 9200283

Group type: EXPERIMENTAL
Intervention: Bismuth-based triple therapy (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bismuth + placebo (n = 50)
Number of subjects: 100
Study: 1305012

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard extracapsular cataract extraction (ECCE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both surgical techniques
Number of subjects: 0
Study: 3895032

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 30153497

Group type: EXPERIMENTAL
Intervention: Potentially Inappropriate Psychotropic drugs (PIP)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Inappropriate background regimen prescription
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Inappropriate antidepressant prescription
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Inappropriate prescription of anxiolytics
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Inappropriate prescription of hypnotics
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Major depression diagnosis
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Bipolar disorder diagnosis
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Current major depressive disorder
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Lower willingness to ask for help
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Potentially inappropriate background regimen prescription
Number of subjects: 703
Study: 29202646

Group type: EXPERIMENTAL
Intervention: 5 mg/1 mL diclofenac HPβCD
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 12.5 mg/1 mL diclofenac HPβCD
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 25 mg/1 mL diclofenac HPβCD
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 50 mg/1 mL diclofenac HPβCD
Number of subjects: 75

Group type: COMPARATOR
Intervention: 1 mL placebo
Number of subjects: 75
Study: 27226212

Group type: EXPERIMENTAL
Intervention: Breastfeeding (human milk)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 10% sucrose solution
Number of subjects: 16
Study: 24636395

Group type: EXPERIMENTAL
Intervention: Vitamin D3, 12,000 IU daily for 12 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 23318611

Group type: EXPERIMENTAL
Intervention: Limb-occlusion-pressure (LOP) group
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (routine method based on patient's systolic blood pressure)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Both groups (with cuff pressure above 225 mm Hg)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Cuff pressure ≤225 mm Hg
Number of subjects: 164
Study: 20303352

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a with ribavirin
Number of subjects: 50

Group type: COMPARATOR
Intervention: peginterferon alpha‐2a
Number of subjects: 50
Study: 18393052

Group type: EXPERIMENTAL
Intervention: Methamphetamine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study: 16581036

Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg co-administered with fluoxetine
Number of subjects: 545

Group type: COMPARATOR
Intervention: Placebo co-administered with fluoxetine
Number of subjects: 545
Study: 12672167

Group type: EXPERIMENTAL
Intervention: 100 mg modafinil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 30
Study: 10715508

Group type: EXPERIMENTAL
Intervention: Patients aware of being part of a study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients unaware of being part of a study
Number of subjects: 0
Study: 9372886

Group type: COMPARATOR
Intervention: External radiotherapy (ER) alone
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: External radiotherapy (ER) + strontium-89 (89Sr)
Number of subjects: 79
Study: 1549632

Group type: EXPERIMENTAL
Intervention: Manual Muscle Test (MMT) grades
Number of subjects: 102
Study: 2862882

Group type: EXPERIMENTAL
Intervention: Intervention program for heavy drinkers
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30000
Study: 31818716

Group type: EXPERIMENTAL
Intervention: OLA-guided therapy
Number of subjects: 991

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: NNRTI-based ART with efavirenz
Number of subjects: 991
Study: 31364397

Group type: EXPERIMENTAL
Intervention: FLARE‐RT (functional lung avoidance radiation therapy)
Number of subjects: 28

Group type: COMPARATOR
Intervention: LUNG‐RT (conventionally planned radiation therapy)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: FLARE‐RT
Number of subjects: 28

Group type: COMPARATOR
Intervention: LUNG‐RT
Number of subjects: 28
Study: 27862904

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) <120 mm Hg
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Hispanics on the US mainland
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Hispanics
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Mainland Hispanics
Number of subjects: 984

Group type: COMPARATOR
Intervention: Hispanics vs non-Hispanics
Number of subjects: 984
Study: 25617858

Group type: EXPERIMENTAL
Intervention: Palmolein
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 28
Study: 23782470

Group type: EXPERIMENTAL
Intervention: InPAct program (interactive patient booklet and standardized training of physicians)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1200
Study: 22074711

Group type: EXPERIMENTAL
Intervention: Viral load arm (clinical monitoring, quarterly CD4 counts, and viral load measurements)
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: CD4 arm (clinical monitoring and CD4 counts)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Clinical arm (clinical monitoring alone)
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: CD4 arm
Number of subjects: 1094
Study: 19449251

Group type: EXPERIMENTAL
Intervention: Focal knee joint cooling (20 min with two 1.5-litre ice bags)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (quiet sitting)
Number of subjects: 11
Study: 16850671

Group type: EXPERIMENTAL
Intervention: Low-dose monophasic oral contraceptive pills
Number of subjects: 70

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 70
Study: 14676238

Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Diabetic-hypertensive patients
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Patient group (hypertensive, diabetic, or both)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Overall analysis including study group variable
Number of subjects: 94
Study: 11506150

Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspiration (MVA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Electric Vacuum Aspiration (EVA)
Number of subjects: 42
Study: 9261292

Group type: EXPERIMENTAL
Intervention: Controlled short-duration hyperventilation (HV) for 1 minute
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8396158

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2876775

Group type: EXPERIMENTAL
Intervention: Tulobuterol (2 mg BID)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Salbutamol (2 mg TID)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tulobuterol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tulobuterol and Salbutamol
Number of subjects: 40
Study: 31992538

Group type: EXPERIMENTAL
Intervention: Residual incompetent tributaries without truncal incompetence
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: No venous incompetence
Number of subjects: 280

Group type: COMPARATOR
Intervention: Incompetent tributaries only
Number of subjects: 280

Group type: COMPARATOR
Intervention: Combined incompetence of truncal vein and tributaries
Number of subjects: 280

Group type: COMPARATOR
Intervention: Presence of perforating vein incompetence
Number of subjects: 280
Study: 29980331

Group type: EXPERIMENTAL
Intervention: 36 months of ADT
Number of subjects: 630

Group type: COMPARATOR
Intervention: 18 months of ADT
Number of subjects: 630
Study: 26810391

Group type: EXPERIMENTAL
Intervention: Power toothbrush
Number of subjects: 109

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 109
Study: 23782864

Group type: EXPERIMENTAL
Intervention: Nurse-led biofeedback-assisted relaxation (night group)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Nurse-led biofeedback-assisted relaxation (morning-night group)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Nurse-led biofeedback-assisted relaxation (morning group)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study: 21715200

Group type: EXPERIMENTAL
Intervention: Coping Strategies Questionnaire after 3 months
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Distraction coping strategy
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Reinterpreting coping strategy
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Catastrophizing coping strategy
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Praying and hoping coping strategy
Number of subjects: 740
Study: 19393999

Group type: EXPERIMENTAL
Intervention: HA-bound spermatozoa
Number of subjects: 241

Group type: COMPARATOR
Intervention: HA-ICSI
Number of subjects: 241
Study: 16917681

Group type: EXPERIMENTAL
Intervention: Additional support programme
Number of subjects: 101

Group type: COMPARATOR
Intervention: Informative programme
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 101
Study: 16200752

Group type: EXPERIMENTAL
Intervention: Heuristic fuzzy logic approach to EMG pattern recognition for multifunctional prosthesis control
Number of subjects: 5
Study: 11988654

Group type: EXPERIMENTAL
Intervention: Diaspirin cross-linked hemoglobin (DCLHb)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 10396195

Group type: EXPERIMENTAL
Intervention: Nedocromil 2%
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fluorometholone 0.1%
Number of subjects: 24
Study: 8583779

Group type: EXPERIMENTAL
Intervention: Epoprostenol infusion (initial rate of 2 ng/kg/min, increased to max 8 ng/kg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study: 2248854

Group type: EXPERIMENTAL
Intervention: 15 ml kg‐1 h‐1 intravenous crystalloid fluid
Number of subjects: 12

Group type: COMPARATOR
Intervention: 5-10 ml kg‐1 h‐1 intravenous crystalloid fluid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low sodium (glucose) solutions
Number of subjects: 12
Study: 6988946

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg orally 12‐18 hours preoperatively and 200 mg intravenously during the subsequent 4 days
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg orally 12‐18 hours preoperatively and 200 mg intravenously during the subsequent 4 days + 2 grams of tinidazole orally as a single dose 12‐18 hours preoperatively
Number of subjects: 84

Group type: COMPARATOR
Intervention: Bacitracin/neomycin tablets during the 3 days immediately prior to operation
Number of subjects: 84
Study: 31667855

Group type: EXPERIMENTAL
Intervention: Superparamagnetic iron oxide (SPIO) nanoparticles detected by a handheld magnetic probe
Number of subjects: 220

Group type: COMPARATOR
Intervention: Radioisotope (RI) method using radioactive colloids (99m Tc) and blue dye (indigo carmine)
Number of subjects: 220
Study: 29340750

Group type: EXPERIMENTAL
Intervention: ARTISS fibrin sealant (Human)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no ARTISS)
Number of subjects: 9
Study: 26296929

Group type: EXPERIMENTAL
Intervention: OTO‐201 4 mg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: OTO‐201 12 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 83
Study: 24482348

Group type: EXPERIMENTAL
Intervention: Postoperative prednisone 30 mg daily × 7 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Postoperative placebo pill daily × 7 days
Number of subjects: 36
Study: 23188903

Group type: EXPERIMENTAL
Intervention: Peri-articular injection of local anaesthetic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Femoral nerve block
Number of subjects: 0
Study: 20083871

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17186396

Group type: EXPERIMENTAL
Intervention: Supervised exercise in addition to routine anticoagulation and class II compression stockings
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine anticoagulation and class II compression stockings without exercise
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups (exercise and control)
Number of subjects: 72
Study: 15168035

Group type: EXPERIMENTAL
Intervention: Whey peptide hydrolysate (WHY)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate (CAHY)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Casein whole protein (C)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Whey whole protein (W)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Peptide hydrolysates (WHY and CAHY)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All solutions (WHY, CAHY, C, W)
Number of subjects: 6
Study: 12704877

Group type: EXPERIMENTAL
Intervention: 5-FU plus FA plus LEV (arm B, 283 pts.)
Number of subjects: 813

Group type: COMPARATOR
Intervention: 5-FU plus LEV (arm A, 279 pts.)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: 5-FU plus LEV with IFNa (arm C, 251 pts.)
Number of subjects: 813
Study: 10022937

Group type: EXPERIMENTAL
Intervention: Proteases (Wobenzym drg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Systemic antiedema and hemostyptic therapy (Dicynone drg and Reparil drg)
Number of subjects: 20
Study: 7484628

Group type: EXPERIMENTAL
Intervention: Compression ratios from 1:1 to more than 40:1 applied to MR images
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Compression at 20:1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Compression ratios tested (including 40:1)
Number of subjects: 3
Study: 2189367

Group type: EXPERIMENTAL
Intervention: High dose beclomethasone dipropionate (750 micrograms three times daily for five days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 389223

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg twice daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg once daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atenolol (any dosage)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atenolol once daily
Number of subjects: 9
Study: 30944686

Group type: COMPARATOR
Intervention: 0.2 mg hydromorphone coadministered with ropivacaine (group H1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.4 mg hydromorphone coadministered with ropivacaine (group H2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.6 mg hydromorphone coadministered with ropivacaine (group H3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0 mg hydromorphone coadministered with ropivacaine (group H0)
Number of subjects: 80
Study: 28288592

Group type: EXPERIMENTAL
Intervention: manualized Short Term Psychodynamic Psychotherapy (mSTPP)
Number of subjects: 109

Group type: COMPARATOR
Intervention: treatment as usual without specific training (tauSTPP)
Number of subjects: 109
Study: 25939591

Group type: EXPERIMENTAL
Intervention: 1,000 mg resveratrol daily for 4 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 66
Study: 23297849

Group type: EXPERIMENTAL
Intervention: Removable dentures supported with four implants
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Fixed reconstruction using eight implants
Number of subjects: 56

Group type: COMPARATOR
Intervention: Various implant retained and/or supported prostheses
Number of subjects: 56
Study: 20571097

Group type: EXPERIMENTAL
Intervention: Low-GDP solution
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard PD fluid
Number of subjects: 33
Study: 19410143

Group type: EXPERIMENTAL
Intervention: 2D planning for small breast size
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2D planning for medium breast size
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2D planning for large breast size
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CT-based planning and 3D planning for medium and large breast sizes
Number of subjects: 20
Study: 17449110

Group type: EXPERIMENTAL
Intervention: Combination of amantadine 100 mg t.i.d. and baclofen 30 mg t.i.d.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cocaine (20 mg and 40 mg doses)
Number of subjects: 8
Study: 14680448

Group type: EXPERIMENTAL
Intervention: Carvedilol (mean daily dose 41.8 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol tartrate (mean daily dose 85 mg)
Number of subjects: 0
Study: 15264940

Group type: EXPERIMENTAL
Intervention: Provider alert
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Provider and scheduler alert
Number of subjects: 409

Group type: COMPARATOR
Intervention: Control (no reminder)
Number of subjects: 409
Study: 10080304

Group type: EXPERIMENTAL
Intervention: Titanium group (n = 22)
Number of subjects: 47

Group type: COMPARATOR
Intervention: High-gold alloy group (n = 25)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study: 8749837

Group type: EXPERIMENTAL
Intervention: Lofepramine (noradrenaline-specific reuptake inhibitor)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Fluoxetine (serotonin-specific reuptake inhibitor)
Number of subjects: 183
Study: 1903230

Group type: EXPERIMENTAL
Intervention: Classical splenorenal shunt
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Esophagogastric devascularization with splenectomy
Number of subjects: 94

Group type: COMPARATOR
Intervention: All three surgical procedures
Number of subjects: 94
Study: 7039519

Group type: EXPERIMENTAL
Intervention: Rapid refeeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard graduated feeding regimen
Number of subjects: 0
Study: 31112788

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 24
Study: 27543832

Group type: EXPERIMENTAL
Intervention: female‐specific group or individual outpatient treatment
Number of subjects: 138
Study: 26417460

Group type: EXPERIMENTAL
Intervention: Cognitive Training Group
Number of subjects: 209

Group type: COMPARATOR
Intervention: Active Control Group
Number of subjects: 209
Study: 22945607

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (50 mg, 4 times a week for 8.5 months)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation
Number of subjects: 321
Study: 21367998

Group type: EXPERIMENTAL
Intervention: Rotation condition
Number of subjects: 15

Group type: COMPARATOR
Intervention: No-rotation condition
Number of subjects: 15
Study: 19150528

Group type: EXPERIMENTAL
Intervention: Shared medical appointment intervention led by an advanced practice nurse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 18604013

Group type: EXPERIMENTAL
Intervention: Intrathecal Pethidine (1mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intrathecal Bupivacaine heavy (2.2ml of 0.5%)
Number of subjects: 60
Study: 14712164

Group type: EXPERIMENTAL
Intervention: EM trial (exercise 30 minutes before the fat meal)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ME trial (exercise 90 minutes after the fat meal)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CON trial (fat meal only)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: EM trial
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ME trial
Number of subjects: 10

Group type: COMPARATOR
Intervention: CON trial
Number of subjects: 10